Bioactive compounds of Eurycoma longifolia (EL) jack were previously shown to reduce omentum fat mass and oestradiol-induced fatty uterine adhesion in rats. However, the exact role of EL on adipogenesis remains unknown. This study sought to investigate the effects of an EL standardized quassinoids-enriched fraction (SQEL) and the pure compound, eurycomanone, on adipogenesis in 3T3-L1 preadipocyte cells. 3T3-L1 cells were induced to differentiate and treated for 8 days. The treatment reduced intracellular accumulation of lipid droplets and triglycerides in the differentiating adipocytes and induced lipolysis in matured adipocytes. The expressions of adipogenic transcription factors and markers were also significantly downregulated during the early stage of differentiation. Furthermore, SQEL also suppressed body weight gain, decreased epididymal and perirenal fat pad mass and size, and reduced the accumulation of fat in the livers of C57BL/6J mice fed with normal or high-fat diet that were concurrently given 5 mg/kg and 10 mg/kg (i.p) of SQEL for 12 weeks. SQEL also improved glucose intolerance and decreased the elevated total cholesterol and triglyceride levels in these mice groups. These findings suggest that SQEL could be explored as an alternative pharmacologic agent inhibiting adipogenesis for the prevention of obesity. 
| INTRODUCTION
Adipocytes play a pivotal role in modulating energy homeostasis and lipid metabolism (Unger, Clark, Scherer, & Orci, 2010) . Adipogenesis is a process of intracellular accumulation of lipid molecules in adipocytes in the event of caloric overabundance (Hausman, DiGirolamo, Bartness, Hausman, & Martin, 2001) . Uncontrolled adipogenesis leads to hypertrophy of adipocytes, which enhances the buildup of fatty tissue mass and eventually contributes to the development of obesity (Fruhbeck, Gomez-Ambrosi, Muruzabal, & Burrell, 2001) . As adipogenesis facilitates the progression of obesity, various studies have focused on inhibiting adipocytes differentiation, downregulating lipogenesis, and enhancing lipolysis as strategies in preventing the development of obesity (Dave et al., 2012; He, Li, Zhao, Wang, & Sun, 2013; Inafuku et al., 2013; Park et al., 2012; Song et al., 2013) .
Various transcription factors and adipogenic genes modulate the tightly controlled process of adipogenesis. Major adipogenic transcription factors such as CCAAT/enhancer-binding protein β (C/EBPβ), peroxisome proliferator-activated receptor γ (PPARγ), and CCAAT/ enhancer-binding protein α (C/EBPα) play a crucial role in coordinating this complex cellular differentiation (Rosen & MacDougald, 2006; White & Stephens, 2010) . In fact, C/EBPβ is expressed upon adipogenic induction and switches on the promoters of the genes encoding PPARγ and C/EBPα, which then activates the expression of adipogenic genes such as fatty acid binding protein (aP2), fatty acid synthetase (FAS), and lipoprotein lipase (LPL) that promotes the progression of adipocytic differentiation (Cristancho & Lazar, 2011; Farmer, 2006) . Interestingly, the activity of transcription factors is regulated at numerous stages including protein acetylation by both acetylase and deacetylase. The histone deacetylase Sirtuin 1 (Sirt1) possesses significant roles in a variety of biological processes including adipogenesis. It was reported that the suppression of PPARγ activity by Sirt1 impaired adipogenesis and induced adipolysis in matured adipocytes (Picard et al., 2004) . Earlier evidence showed that overexpression of Sirt1 attenuates adipocyte differentiation by reducing the expression of PPARγ and C/EBPα in 3T3-L1 cells (Picard et al., 2004) . Similarly, reduced Sirt1 levels promote PPARγ acetylation and C/EBPα activity, which leads to adipocyte differentiation (Qu et al., 2016) . Conversely, the inhibitory effect of PPARγ on Sirt1 activity (Han et al., 2010) and modulation of Sirt1 expression by C/EBPα during adipogenesis (Jin et al., 2010) indicate that Sirt1 could be regulated by adipogenic transcription factors as well. Hence, improving our understanding on the molecular mechanisms in adipogenesis could pave ways for the identification of therapeutic targets against metabolic diseases that are quickly becoming global concerns.
Exercise, diet, and lifestyle modifications are highly advocated in the management of obesity. However, pharmacological therapy may provide additional benefit in ameliorating comorbidities and promoting adherence to behavior modifications, which in turn may improve physical functions for greater physical activity (Apovian et al., 2015) . Currently, several prescriptive antiobesity drugs can be used to suppress appetite, reduce lipid absorption, and enhance fat oxidation for weight management of obese individuals (Padwal & Majumdar, 2007) . However, poor efficacy and serious side effects of those drugs have led to their withdrawal from the market leaving only a handful of drugs that can be consumed for the said purpose.
Recent studies have also shown the potentials of compounds of natural origin such as quassinoids and alkaloids as alternative pharmacotherapeutic agents to manage obesity (Mohamed, Ibrahim, Elkhayat, & El Dine, 2014) . Quassinoids that include the pure compound, eurycomanone, can be found in Eurycoma longifolia (EL) Jack, a tropical plant classified under Simaroubaceae family that is widely known as "Tongkat Ali" in Malaysia. The root of this plant is a popular traditional medication for fever after birth, boils, ulcer wound healing treatment and also acts as energy booster among men (Low, Choi, et al., 2013) . Quassinoids from EL were reported to have biological activities such as antiplasmodial, anticancers, pro-fertility, and aphrodisiac activities in males (Bhat & Karim, 2010) . In addition, EL was also shown to have a synergistic effect with other bioactive compounds in reducing body weight (Solomon, Erasmus, & Henkel, 2014; Talbott, Talbott, George, & Pugh, 2013) . However, to date, there is limited information on the effects of EL-derived quassinoids in adipogenesis including the mechanisms involved. Thus, the present study aims to investigate the potential lipid modulation effects of a standardized quassinoids-enriched fraction of E. longifolia (SQEL) and eurycomanone in adipocytes and in high-fat diet (HFD)-induced obese mice.
| MATERIALS AND METHODS

| Preparation of the standardized quassinoidsenriched fraction of Eurycoma longifolia (SQEL)
The standardized quassinoids-enriched fraction of EL from the root was prepared following the method established previously by . SQEL contains 14.49 ± 0.26% of eurycomanone, 7.39 ± 0.17% epoxyeurycomanone, 0.72 ± 0.06% 13,21-dihydroeurycomanone, and 9.54 ± 0.22% w/w eurycomanol (Al-Salahi et al., 2013; Low, Teh, Yuen, & Chan, 2011) . The pure compound, eurycomanone, was purchased, and its purity (>96%) was verified using HPLC (Chengdu Biopurify Phytochemicals Ltd., Chengdu, China).
| Cell culture and differentiation
Mouse 3T3-L1 preadipocyte cells (ATCC® CL-173™) were maintained in high glucose Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (10,000 U/ml) in a humidified atmosphere of 5% CO 2 at 37°C. Two days after seeding, the confluent preadipocytes were induced to differentiate in induction medium containing 0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, and 10 μg/ml insulin in complete DMEM for 2 days. This medium was replaced with complete DMEM containing 10 μg/ml insulin and used to maintain the cell culture for 3 days and then changed every 3 days.
| Cell viability and cytotoxicity
Cell viability and cytotoxicity of SQEL and eurycomanone were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were cultured in 96-well plate at optimum density. After 24 hr, the cells were either treated with vehicle control or SQEL (0.4-100 μg/ml) or eurycomanone (0.4-100 μg/ml) for 72 hr. The viability of the differentiating preadipocytes was assessed by treating the 2 days postconfluent cells with SQEL (12.5-100 μg/ ml) and eurycomanone (3.1-25 μg/ml) in differentiation medium for 48 hr. To study the effects of SQEL and eurycomanone on the viability of matured adipocytes, 2 days postconfluent cells were induced to differentiate for 8 days as mentioned previously and treated with SQEL (12.5-100 μg/ml) and eurycomanone (3.1-25 μg/ml) for 48 hr. Then, 2 mg/ml of MTT in 1X phosphate-buffered saline (PBS) were added to each well and incubated for 3 hr at humidified atmosphere of 5% CO 2 at 37°C. The cell culture medium was removed, followed by the addition of 100 μl of DMSO and then mixed at 300 rpm for 15 min.
Absorbance reading was measured at 570 nm. The effect of SQEL and eurycomanone on cell viability of 3T3-L1 preadipocytes, differentiating preadipocytes and matured adipocytes, was determined as the percentage of cell viability compared to vehicle control cells, assigned with 100% viability. The half maximal inhibitory concentration (IC 50 ) was determined using GraphPad Prism software version 6.0 (GraphPad Software Inc., San Diego, CA). 
| Oil Red O staining
| Triglyceride quantification assay
Differentiated cells treated with and without SQEL (12.5-100 μg/ml) or eurycomanone (3.1-25 μg/ml) or sulforaphane (0.9 μg/ml) were washed with 1X PBS, scraped, and homogenized with 5% NP-40 solution. Sulforaphane was used as a positive control (Choi et al., 2012) . Intracellular triglyceride contents were quantified from the cell lysates using a triglyceride quantification kit (Biovision, USA) following the manufacturer's protocol.
| Lipolysis assay
3T3-L1 cells were induced to differentiate as mentioned above.
Matured adipocytes were treated with and without SQEL (12.5-100 μg/ml) or eurycomanone (3.1-25 μg/ml) or isoproterenol (2.1 μg/ml) for 48 hr, and the culture medium was collected. Isoproterenol was used as a positive control for release of glycerol from triglycerides (Zimmermann et al., 2004) . The extent of lipolysis induced by the treatment was determined by quantifying the released glycerol into the medium using a Glycerol Quantification Kit (BioVision, USA) according to the manufacturer's instructions.
| Immunoblotting analysis
3T3-L1 cells were washed twice and harvested with cold 1X PBS.
The cell pellet was homogenized in RIPA lysis buffer (1X PBS, 1% Nonidet® P-40 substitute, 0.1% sodium dodecyl sulfate and 0.5% sodium deoxycholate) containing 1X of protease inhibitor mixture (1:1,000), C/EBPα (1:1,000), FAS (1:4,000), Sirt1 (1:1,000), and β-actin (1:20,000), overnight at 4°C. Then, the membranes were washed 5 times and incubated with respective horseradish peroxidase-conjugated secondary antibodies (DAKO, Denmark) for 2 hr at room temperature. The bands were visualized with enhanced chemiluminescence (GE, UK) and exposed to X-ray film (Fujifilm, Japan).
Densitometric analysis was performed using Image Studio Lite version 4.0.21 (LI-COR Biosciences) software, and relative protein expression was determined by comparing the intensity of the band to those of the vehicle control.
| Quantitative real-time PCR
Total RNA from 3T3-L1 cells was extracted using the RNAeasy mini kit 
| Animal experiments
Six-week-old C57BL/6J male mice were housed in individually venti- respectively. ND group were fed with rodent maintenance diet (#1324, Altromin, Germany), and HFD group were fed with rodent HFD (60% kcal fat; C1090-60, Altromin, Germany) and water ad libitum for 12 weeks. Both diet groups received 0.9% saline and various dosages of SQEL via intraperitoneal route, whereas 10 mg/kg orlistat was given via oral route once every 2 days for 12 weeks.
Food intake and mice body weight were measured 2 days once. Prior to sacrifice at Week 12, oral glucose tolerance test and intraperitoneal insulin tolerance test were performed. At the end of the treatment period, all mice were fasted for 6 hr and sacrificed by carbon dioxide inhalation. Liver, epididymal, and perirenal white adipose tissues from all groups were excised, weighted and some were fixed in 10% formalin for histopathology. Blood samples from the animals were collected via cardiac puncture, and serum was separated and stored at −20°C for biochemical analysis.
| Oral glucose tolerance test
Fasting blood glucose level was measured in all animals at 6 hr postfasting via tail prick using an Accu-check® glucometer (Roche Diagnostics, Germany). Glucose (2 g/kg) was then administered via oral gavage and blood glucose was measured again at time points of 30, 60, 90, and 120 min postgavage. The area under the curve of glucose level was calculated using GraphPad Prism software version 6.0 (GraphPad Software Inc., San Diego, CA).
| Intraperitoneal insulin tolerance test
Fasting blood glucose level was measured in all animals at 5 hr postfasting via tail prick using an Accu-check® glucometer (Roche Diagnostics, Germany). Then, 0.75 IU/kg insulin was injected intraperitoneally, and blood glucose was measured again at 15, 30, 60, 90, and 120 min postinjection. The area under the curve of glucose level was calculated using GraphPad Prism software version 6.0 (GraphPad Software Inc., San Diego, CA).
| Serum biochemistry
Collected sera were sent to Hematology & Biochemistry Clinical Laboratory, Veterinary Laboratory Service Unit, Faculty of Veterinary Medicine, University Putra Malaysia, to determine total cholesterol and serum triglycerides using Dimension® Xpand® Plus clinical chemistry system (SIEMENS Healthcare Diagnostics Inc.).
| Liver and fat tissues histological analysis
Liver and fat tissues were fixed in 10% buffered formalin, dehydrated and embedded in paraffin. Tissue sections of 4 μm thick were stained with hematoxylin and eosin to examine the morphology. Photomicrographs were taken using bright field LEICA DM 2000 microscope with LEICA ICC50 HD camera (Leica Microsystems, Germany). The mean diameter of the imaged adipocytes was measured using the ImageJ software with Adiposoft plugin at auto mode (Galarraga et al., 2012) .
The Adiposoft application was calibrated to identify cells with diameter range (20-200 μm) and measuring scale of 0.95 μm/pixel.
| Statistical analysis
Data are expressed as mean ± Standard Error Mean (SEM) from n number of experiments. Student's t test was performed for comparison between two groups. Comparison between more than two groups was analyzed by one-way analysis of variance followed by
Bonferroni's multiple comparison tests using Graph Pad Prism (Version 6.0, Graph Pad Software Inc., San Diego, CA). P value <.05 was considered to be statistically significant.
| RESULTS
| SQEL and eurycomanone inhibit adipogenesis of 3T3-L1 cells
Cytotoxicity of both SQEL and eurycomanone on preadipocytes was evaluated using MTT assay. Eurycomanone exerted greater cytotoxicity to 3T3-L1 cells with an IC 50 value of 70.8 ± 11.7 μg/ml compared to SQEL with an IC 50 value of 160.3 ± 36.7 μg/ml ( Figure 1a) . Therefore, the concentration range of 12.5-100 μg/ml for SQEL and 3.1-25 μg/ ml for eurycomanone were chosen for subsequent experiments. The chosen concentrations of SQEL and eurycomanone were further tested for potential cytotoxicity during the differentiation of preadipocytes and in the mature adipocytes, respectively. Both SQEL and eurycomanone were not cytotoxic to both the differentiating preadipocytes and matured adipocytes even at the highest tested concentration (Figure 1b,c) .
Next, the potential antiadipogenic effects of SQEL and eurycomanone in 3T3-L1 cells were assessed in the differentiating cells treated with SQEL (12.5-100 μg/ml) and eurycomanone (3.1- inhibition even with 25 μg/ml eurycomanone treatment while only 73% inhibition at 100 μg/ml SQEL concentration. Because the antiadipogenic effect of SQEL and eurycomanone was achieved at the concentrations that did not exert cytotoxicity, both have effectively inhibited adipogenic differentiation in 3T3-L1 cells.
| SQEL and eurycomanone reduce lipogenesis and induce adipolysis
Lipid accumulation is the most prominent marker of adipogenesis, and its quantification is used to assess the extent of adipocyte 5-100 μg/ml) and eurycomanone (3.1-25 μg/ml). Cell viability was determined by comparing with vehicle control (100%) and media blank (0%) by MTT reduction assay. Data are presented as the mean ± SEM of three independent experiments performed in triplicate. Sf = sulforaphane; Iso = isoproterenol Hence, the effect of SQEL and eurycomanone on the regulation of adipogenesis-associated proteins and genes in differentiating 3T3-L1 cells harvested on Day 2 of differentiation was studied. The protein expressions of both PPARγ isomers (PPARγ1 and PPARγ2) were reduced after SQEL and eurycomanone treatments, with significant reduction observed for only PPARγ2 and C/EBPα (Figure 3a,b) . Similarly, the protein expression of FAS was also significantly downregulated by SQEL and eurycomanone after 2 days (Figure 3a,b) . Moreover, the mRNA expression of PPARγ decreased with eurycomanone treatment while both SQEL and eurycomanone significantly reduced the mRNA level of C/EBPα in the differentiating cells (Figure 3c) . Furthermore, the mRNA levels of LPL and Kruppel-like factor 15 (KLF15) that are positively regulated by PPARγ were significantly reduced with SQEL and eurycomanone treatments (Figure 3c ). Interestingly, significant upregulation in the protein and mRNA expression of Sirtuin1 (Sirt1) HFD than ND (Figure 4c ). The reduction in weight gain of both NDand HFD-fed mice groups was comparable with those given standard drug orlistat.
| SQEL improves impaired glucose tolerance but not insulin sensitivity in C57BL/6J mice
Impaired glucose tolerance was observed in the HFD-fed mice group compared with the ND-fed group (Figure 4d ). Significantly lower glucose intolerance observed in the ND-fed mice group supplemented with 5 mg/kg and 10 mg/kg SQEL as well as in the HFD-fed mice group treated with 10 mg/kg SQEL compared with its respective saline control mice group (Figure 4e ). Orlistat treatment has significantly reduced glucose intolerance in both the ND and HFD-fed mice groups.
On the other hand, insulin sensitivity was not affected in mice on both ND and HFD with and without SQEL treatment (Figure 4f ). However, orlistat treatment significantly improved insulin sensitivity in mice group given HFD (Figure 4g ).
| SQEL reduces adipose tissue mass in C57BL/6J mice
Saline or SQEL-treated ND-fed mice possessed lower epididymal and perirenal fat pad mass compared with those fed with HFD. SQEL treatment did not alter both epididymal and perirenal fat volume in mice on ND ( Figure S1A ). However, in the HFD-fed mice group treated with SQEL, epididymal and perirenal fat pad mass was reduced significantly compared to its saline control (Figure 5a,b) . The decrease in fat mass was comparable with the reduction seen with standard antiobesity drug orlistat (Figure 5a,b ). An unanticipated finding was noted, whereby, the ND-fed mice possessed significantly higher liver weight compared with mice fed with HFD for 12 weeks. However, there was an insignificant reduction in the liver weight of mice fed with ND and treated with SQEL for the same period (Figure 5c ). On the other hand, SQEL treatment in mice fed with HFD showed a significant increase in liver weight compared to its saline control while orlistat treatment only exhibited very mild reduction. However, SQELmediated increase in liver weight of mice on HFD was not significantly more than the liver weight of ND-fed saline control mice (Figure 5c ). (Table 1) .
| Effects of SQEL treatment on fat accumulation in liver and adipose tissue hypertrophy in C57BL/6J mice
| DISCUSSION
In the present study, the antiadipogenic effect of a quassinoids composition (SQEL) and the pure compound eurycomanone from EL Jack was Note. Body weight gain, lipid profile, and blood glucose of mice given normal diet and high-fat diet and treated with 0.9% saline, 5 mg/kg SQEL, 10 mg/kg SQEL, and 10 mg/kg orlistat. Data are presented as the mean ± SEM, n = 7-8.
*p < .05. **p < .01. ***p < .001 versus control (0.9% saline). ****p < .0001 versus 0.9% saline of normal diet.
investigated. We showed that SQEL and eurycomanone significantly inhibited adipogenesis in differentiating 3T3-L1 cells. Moreover, both SQEL and eurycomanone also induced lipolysis in mature adipocytes and resulted in increased glycerol content but reduced intracellular triglycerides. The pure compound eurycomanone was found to have greater in vitro antiadipogenic effect compared with the purified aqueous SQEL that contains about 32% quassinoids including 14% of eurycomanone.
Adipogenesis is a highly controlled process governed by a complex network of transcription factors. PPARγ and C/EBPα are key adipogenic transcription factors that initiate the expression of pro-adipogenic markers for the establishment of matured adipocyte phenotype (Moseti, Regassa, & Kim, 2016; Rosen, 2005) . Cultured preadipocytes will proliferate to achieve growth arrest phase and begin to express PPARγ and C/EBPα upon adipogenic induction by a cocktail of hormones (Farmer, 2006; Gregoire, Smas, & Sul, 1998) and PPARγ2 as a result of splicing and using alternate promoter (Zhu et al., 1995) . PPARγ2 is the isoform that plays the regulatory role in adipogenesis while PPARγ1 has no effect in adipogenic differentiation (Ren, Collingwood, Rebar, Wolffe, & Camp, 2002) . This suggests that the downregulation of PPARγ2 has a significant implication on adipocyte differentiation. In the current study, SQEL and eurycomanone treatments for 48 hr reduced the expression of both PPARγ isomers but significant changes were observed only in PPARγ2 protein expression. Surprisingly, sulforaphane treatment resulted in the upregulation of PPARγ expression during the early stage of adipogenesis but significantly reduced terminal differentiation and triglyceride accumulation in 3T3-L1 cells suggesting that the compound may reduce the expression of PPARγ in the later stage of adipogenic differentiation. These results are in agreement with a previous report whereby, significant suppression of PPARγ expression was observed only after 6 days of sulforaphane treatment in differentiation medium (Choi et al., 2012) .
On the other hand, PPARγ and C/EBPα are also responsible for the expression of adipocyte-specific genes including FAS, LPL, and KLF15, which are involved in the formation of mature adipocytes (Farmer, 2006) . A former study showed that the rate of FAS synthesis is increased during the early phase of adipogenic differentiation that is attributed to the deposition of cytoplasmic lipid in 3T3-L1 cells (Student, Hsu, & Lane, 1980) . In addition, LPL, an early marker for adipogenesis, was found to be elevated in adipocytes (Vu, Ong, Clemens, & Kern, 1996) , and its overexpression in mice has been shown to promote obesity (Delezie et al., 2012) . Furthermore, the DNA-binding transcriptional regulator, KLF15, is also induced during adipogenesis to increase the PPARγ2 gene promoter activity and its inhibition blocked differentiation in 3T3-L1 cells (Mori et al., 2005) . Findings from the present study
showed that the expression of FAS protein, mRNA expression levels of LPL, and KLF15 were significantly downregulated in 3T3-L1 cells treated with SQEL and eurycomanone compared to vehicle control cells.
Therefore, the reduction of adipogenic-specific genes and protein In addition to PPARγ and C/EBPα that play a pivotal role in the transcriptional control of adipocyte differentiation in vitro, earlier reports have identified the involvement of metabolic regulatory factors such as sirtuin (Sirt) proteins in adipogenesis (Cho et al., 2009 ). The activation of Sirt1 has been shown to block adipocyte formation, whereas its inhibition leads to increase in adipocyte number and eventually promotes the expression of adipogenic markers (Backesjo, Li, Lindgren, & Haldosen, 2006) . During the early stage of adipogenesis, upregulation of Sirt1 protein could reduce the expression of PPARγ and inhibit adipocyte maturation (Kim et al., 2015) . Besides, Mayoral and colleagues (2015) had demonstrated that Sirt1 knock-out mice on HFD displayed PPARγ hyperactivity and eventually leads to adipocyte hypertrophy. Moreover, overexpression of Sirt1 was also previously shown to impair triglyceride accumulation in 3T3-L1 cells (Imamura et al., 2017) , suggesting that Sirt1 could be the upstream regulator of adipogenic transcription factors PPARγ and C/EBPα in modulating adipogenesis. Previously, nuclear translocation of Sirt1 was reported to reduce the expression of PPARγ and its downstream adipogenic proteins, which then inhibits 3T3-L1 adipocyte differentiation . In addition, Picard and colleagues (2004) increased Sirt1 expression during adipogenesis also promotes deacetylation of PPARγ, which then impairs PPARγ transcriptional activity and inhibits adipogenesis in 3T3-L1 cells (Kim et al., 2015) . In the present study, we found that the mRNA and protein expression of Sirt1 during the early phase of adipogenesis was significantly upregulated together with downregulation of PPARγ, C/EBPα, and other adipogenic-associated markers by SQEL and eurycomanone treatments. This finding is suggestive of the possible involvement of Sirt1/PPARγ signaling in SQEL and eurycomanone-mediated adipogenesis inhibition in 3T3-L1 cells. In fact, several phytochemicals, including agrimol B, fisetin and resveratrol, were also shown to inhibit adipogenesis via Sirt1/PPARγ signaling (Costa et al., 2011; Kim et al., 2015; Wang et al., 2016) .
Several reports have shown the correlation of adipogenesis and the development of obese condition (Nishimura et al., 2007; Spiegelman & Flier, 1996) . Phytochemicals including curcumin, rutin, and clerodane diterpene have been shown to inhibit the progression of adipogenesis in 3T3-L1 cells as well as obesity in C57BL/6J mouse model (Beg et al., 2015; Choi, Park, Choi, & Lee, 2006; Ejaz, Wu, Kwan, & Meydani, 2009) In the present study, SQEL treatment not only decreased the weight of epididymal and perirenal adipose tissues but has also reduced the adipose tissue size of mice on HFD. This shows that the development of epididymal and perirenal adipose tissues was reduced in the presence of SQEL, possibly due to the inhibitory effect of triglyceride accumulation in fat cells as demonstrated by the inhibition of adipogenesis and cytosolic lipid accumulation in vitro. Interestingly, our findings also revealed that weight gain was prevented in mice without calorie intake reduction. These results are consistent with other previous studies that showed weight gain in animal models could be prevented without food intake suppression (Beg et al., 2015; Inafuku et al., 2013; Sharma, Kim, Kim, Park, & Rhyu, 2017; Song et al., 2013) . This then suggests that SQEL may regulate body weight gain by boosting calorie expenditure via a mechanism that has yet to be determined. It is shown that increased calorie expenditure could be mediated through the action of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) (Gao et al., 2009 ).
PGC-1α is known to stimulate adaptive thermogenesis in brown fat by upregulating uncoupling protein 1 (UCP-1), which in turn increases oxidative type 1 fiber differentiation and enhances fatty acid metabolism in the muscle. In this regard, Gao et al., (2009) (UCP-1) pathway in increased calorie expenditure in mice models (Choi, Kim, Koh, & Lee, 2017; Kudo et al., 2015) . AMPK regulates energy metabolism by stimulating the interaction between PGC1α and PRDM16 resulting in increased mitochondrial biogenesis, thermogenesis, and energy expenditure . Another study further demonstrated that AMPK could increase the expression of Sirt1 and enhances mitochondrial biogenesis through PGC1α (Fernandez-Marcos & Auwerx, 2011) . Hence, it remains to be confirmed in future studies whether SQEL could increase calorie expenditure via these pathways.
Hyperglycemia and insulin resistance are strongly associated with obesity. Prior studies have shown that C57BL/6J mice fed with HFD have elevated blood glucose level (Winzell & Ahren, 2004) and an antiobesity compound treatment improved glucose tolerance (Chen, Sang, Li, He, & Ma, 2017) . Results from this study show that the development of glucose intolerance in HFD mice was significantly inhibited by 12 weeks of SQEL treatment. Even though the time course of glucose clearance in HFD-fed saline control mice was delayed compared with that of the ND-fed mice, SQEL also improved glucose clearance significantly in mice on ND. On the other hand, insulin is the key regulator of adipocyte morphology whereby it promotes the differentiation of preadipocytes to adipocytes and stimulates lipogenesis as well inhibiting lipolysis in mature adipocytes. In fact, adipocytes are one of the cell types that are more sensitive to insulin, and hence, impaired response towards insulin signaling on metabolism and glucose transport in adipose tissue will lead to insulin resistance in obese individual (Kahn & Flier, 2000) . However, our attempt to elucidate the effect of SQEL treatment on insulin sensitivity could not be accomplished because insulin resistance was not observed in both ND-and HFD-fed mice groups, likely due to a shorter study period.
Previously, significant insulin resistance was observed in mice fed with HFD for 16 weeks (Fraulob et al., 2010) and targeted mutagenesis or transgenesis of genes required for insulin action and insulin secretion in mice (Nandi, Kitamura, Kahn, & Accili, 2004) would yield better animal model to be used for studies on insulin resistant. As PPARγ activation has been shown to induce the expression of a number of genes involved in the insulin signaling cascade (Leonardini, Laviola, Perrini, Natalicchio, & Giorgino, 2010) , inhibition of PPARγ by SQEL treatment could have led to the lack of effect on insulin sensitivity in normal although glucose intolerance was reduced.
Histological analysis of liver sections of HFD-fed mice revealed the accumulation of abundant lipid droplets compared with mice on ND, a prominent sign of hepatic steatosis strongly associated with obesity (Fabbrini, Sullivan, & Klein, 2010) . Liver sections of SQELtreated mice fed with ND exhibited normal histology similar to orlistat treatment. Moreover, mice on HFD supplemented with SQEL significantly attenuated the progression of fatty liver disease evidenced by a drastic reduction in the number of lipid droplets in the liver. On the other hand, liver histology of mice received SQEL did not show any sign of inflammation or cytotoxicity, suggesting that increased liver weight was not attributed to liver damage. Interestingly, these findings are comparable to the effects of orlistat treatment in preventing the development of steatohepatitis in obese individuals (Harrison et al., 2003) and indicate that SQEL can intensely suppress the pathological sign in the liver.
Hypertriglyceridemia and hypercholesterolemia are associated with increased risk for obesity as there is a significant correlation between impaired lipid metabolism and obesity (Eisinger et al., 2014; Subramanian & Chait, 2012) . Previously, it was shown that C57BL/6J mice on obesogenic diet had elevated levels of serum triglycerides and cholesterol compared with those on ND (Beg et al., 2015; Song et al., 2013) . However, in the present study, serum total cholesterol but not triglyceride levels were significantly higher in mice fed with HFD compared with those on ND. Nevertheless, decreased level of circulating triglycerides and insignificant change in serum triglycerides have also been found in C57BL/6J mice fed with HFD compared with mice fed with standard diet previously (Eisinger et al., 2014; Ji et al., 2014) . In fact, high-fat consumption or reduced carbohydrate intake could lessen triglyceride production and/or induce triglyceride clearance that eventually lowers circulating level of triglycerides in obese mouse model (Guo, Jou, Gavrilova, & Hall, 2009) .
Results from the present study demonstrated that SQEL treatment reduces both total cholesterol and triglycerides levels in mice regardless of the types of diet given. These outcomes indicate that SQEL modulates triglyceride and cholesterol metabolism both in normal and obese mice.
| CONCLUSION
Thus far, results from the present study revealed that SQEL significantly attenuated lipid accumulation and adipocyte differentiation of 3T3-L1 cells. Intervention with SQEL also suppressed the expression of main transcriptional regulator PPARγ and CEBPα followed by downregulation of adipogenic-specific protein and mRNA level including FAS, LPL, and KLF15 probably via Sirt1/PPARγ signaling. In addition, the administration of SQEL decreased body weight gain and adipose tissue hypertrophy induced by HFD in vivo. Moreover, supplementation of SQEL also improved glucose clearance, decreased serum triglycerides and cholesterol levels in both ND-and HFD-fed mice.
Additionally, the development of hepatic steatosis was also significantly prevented in the obese mouse supplemented with SQEL. Collectively, our results are strongly suggestive of the novel effect of SQEL in inhibiting adipogenesis and high therapeutic potentials in preventing the development of obesity.
